Medigene AG

🎉 Exciting milestone for Medigene AG🎉: U.S. FDA Clearance of IND application for MDG1015, a first-in-class, third generation TCR-T therapy for multiple solid tumor indications🩺 We are thrilled to announce that our Investigational New Drug (IND) application for MDG1015 has been officially cleared by the FDA, an important step toward starting our phase 1 clinical trial EPITOME1015-I to treat advanced solid tumors, pending additional financing. This is a significant step in our mission to bring our innovative third generation TCR-T-therapy to patients and to become a leading company with a range of different TCR-guided therapies for patients suffering from multiple advanced solid tumor types. We are committed to start treating patients as soon as possible and hope to initiate the trial by the end of 2024 pending additional financing. The trial will include a dose escalation followed by an expansion part and will assess safety, feasibility and preliminary efficacy of MDG1015 in multiple solid tumor indications. We are hopeful and eager to explore the potential of MDG1015 to improve cancer treatments for patients. Swipe below to find out what makes our TCR-T therapy stand out and read the full PR here: https://lnkd.in/emfCZDqw #Platform2Patient #MDG1015 #TCRT #ClinicalTrials #SolidTumors

Our Head of Clinical Development Kirsty Crame - van Nierop will join ESMO congress 2024 in Barcelona. She will present the latest data in a poster format and provide valuable insights into our research initiatives showcasing recent advances in the Company's TCR library targeting KRAS and the UniTope & TraCR technology, a universal tagging and tracking system for TCR T cells. The abstracts have been released on the ESMO congress website: https://lnkd.in/dpUGangU 📅 Poster session on Saturday, September 14, 2024, 12-1 pm CEST  #ESMO24

Selwyn Ho and James Cornicelli will join the H.C. Wainwright 26th Annual Global Investment Conference in NY from Sep 9-11, 2024 and looking forward to discussing Medigene AG's ability to generate optimal potential best-in-class, specific, sensitive, and safe TCRs for use across various modalities, including TCR-T therapies, TCR-T cell engagers, and TCR-NK cell therapies. Additionally, they are excited to highlight the recent U.S. FDA clearance of the IND application for MDG1015, a first-in-class TCR-T therapy targeting multiple solid tumor indications. More details on MDG1015 here: https://lnkd.in/d6k_fakE If you missed the announcement about the FDA clearance, you can follow this link for the full PR: https://lnkd.in/emfCZDqw More details on the conference here: https://lnkd.in/eun3Fzw

Medigene AG will present at Annual German Fall Conference 2024 in Frankfurt 🎉 The German Fall Conference uniting financial analysts, investors, financial journalists, and other key players in the capital market area, offers us a valuable opportunity to showcase our latest accomplishments and share our vision for the future. #Herbstkonferenz #GermanFallConference #PLACEtoBE #HK24

Medigene AG secures two additional patents for technologies in its End-to-End Platform Read here the full PR:https://lnkd.in/dzSpqWrM Find out more about our End-to-End Platform technologies here: https://lnkd.in/eDjmquVJ #TCRT #platform2patient

Medigene AG will present at upcoming investor conferences. Read here the PR: https://lnkd.in/dDwddneN More details on the conferences: German Fall Conference 2024: https://lnkd.in/dxF2MfQJ H.C. Wainwright 26th Annual Global Investment Conference 2024: https://lnkd.in/eun3Fzw Baader Investment Conference 2024: https://lnkd.in/dybEaPm

The recent approval of the first TCR-T cell therapy marks a significant milestone in the field of oncology, a moment that has been years in the making. TCR-T therapies hold tremendous promise, especially for the treatment of solid tumors, but their journey to this point has been fraught with challenges. However, the landscape of TCR-T therapy has undergone a remarkable transformation over the past decade. At Medigene AG, we are leveraging the latest scientific advancements within our End-to-End Platform, enabling us to develop TCR-guided therapies including TCR-T Therapies that are not only safe but also durable and effective. Our CEO, Selwyn Ho, recently discussed with Cormac Sheridan of S&S the long and complex journey of TCR-T therapies and what’s next in the exciting field of TCRs. 🔊Listen here: https://lnkd.in/dg7nusfC #TCRT #platform2patient 

WuXi Biologics Deutschland und Medigene AG haben eine 3-jährige Forschungskooperation für Off-the-Shelf TCR-gesteuerte T-Zell-Engager abgeschlossen. Die Zusammenarbeit kombiniert die jeweilige Expertise beider Unternehmen mit Medigene AG TCR-Generierungs- und Charakterisierungsfähigkeiten und WuXi Biologics branchenführender TCE-Plattform sowie der firmeneigenen bispezifischen Antikörperplattform WuXiBody™. Die Kooperation hat das Ziel bispezifischen Therapeutika zu generieren, die eine äußerst spezifische und gezielte Immunreaktionen hervorrufen können und die Behandlungsmöglichkeiten für Patienten verbessern.

Today, Medigene AG reported half-year 2024 financial results and provided a corporate update. Read here the full PR: https://lnkd.in/eAErazKA The Company will host a conference call today, August 14, 2024, at 3.30 pm CEST / 9.30 am EST. Registration for the conference call: https://lnkd.in/dtXBNNmQ Join the live webcast here: https://lnkd.in/dH-9Yrnv #MedigeneAG #platform2patient

Medigene AG will report half-year 2024 financial results on August 14, 2024. The Company will host same day a conference call at 3.30pm CEST / 9.30am EDT.  In addition to the financial results for the first six months of 2024, Medigene AG will provide a corporate update including its new partnership with WuXi Biologics. Read here the full PR: https://lnkd.in/dFsdNjpy Register for the conference call here: https://lnkd.in/dtXBNNmQ Join the live webcast here: https://lnkd.in/dH-9Yrnv